- Home
- VOR
as 09-16-2025 4:00pm EST
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 261.0M | IPO Year: | 2021 |
| Target Price: | $3.90 | AVG Volume (30 days): | 4.4M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -17.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.13 - $3.29 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Vor Biopharma Inc. (VOR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Reprogrammed Interchange LLC | VOR | 10% Owner | Sep 15 '25 | Sell | $1.64 | 400,000 | $656,320.00 | 33,228,487 | |
| Reprogrammed Interchange LLC | VOR | 10% Owner | Sep 12 '25 | Sell | $1.75 | 300,000 | $526,230.00 | 33,228,487 | |
| Reprogrammed Interchange LLC | VOR | 10% Owner | Sep 11 '25 | Sell | $1.83 | 284,805 | $521,420.99 | 33,228,487 | |
| Reprogrammed Interchange LLC | VOR | 10% Owner | Sep 10 '25 | Sell | $1.82 | 350,000 | $635,285.00 | 33,228,487 | |
| Reprogrammed Interchange LLC | VOR | 10% Owner | Sep 9 '25 | Sell | $2.00 | 449,226 | $898,631.69 | 33,228,487 | |
| Reprogrammed Interchange LLC | VOR | 10% Owner | Sep 8 '25 | Sell | $1.99 | 464,421 | $924,058.46 | 33,228,487 | |
| Reprogrammed Interchange LLC | VOR | N/A | Aug 26 '25 | Sell | $2.08 | 284,190 | $591,342.55 | 33,228,487 | |
| Reprogrammed Interchange LLC | VOR | N/A | Aug 25 '25 | Sell | $2.12 | 387,346 | $819,740.34 | 33,228,487 |
Latest Vor Biopharma Inc. News
VOR Breaking Stock News: Dive into VOR Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
MT Newswires
3 months ago
Vor Biopharma Licenses Autoimmune Drug From RemeGen, Names New CEO
GlobeNewswire
3 months ago
Vor Bio Announces $175 Million Private Placement
GlobeNewswire
3 months ago
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
Simply Wall St.
3 months ago
Estimating The Fair Value Of Vor Biopharma Inc. (NASDAQ:VOR)
MT Newswires
4 months ago
Baird Downgrades Vor Biopharma to Neutral From Outperform
MT Newswires
4 months ago
Stifel Downgrades Vor Biopharma to Hold From Buy
MT Newswires
4 months ago
HC Wainwright Downgrades Vor Biopharma to Neutral From Buy
Compare VOR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VOR Vor Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.